Kinase News and Research

RSS

Scientists outline molecular blueprints of tiny cellular 'nanomachine'

Scientists have drawn up molecular blueprints of a tiny cellular ‘nanomachine’, whose evolution is an extraordinary feat of nature, by using one of the brightest X-ray sources on Earth.

21 Dec 2015

TSRI-led study finds potential new therapeutic approach for hard-to-treat breast cancers

Findings from a new study led by scientists from the Florida campus of The Scripps Research Institute (TSRI) suggest a potent new therapeutic approach for a number of hard-to-treat breast cancers.

21 Dec 2015

Combination therapy can help overcome endocrine resistance in women with advanced breast cancer

Data collected in Japanese and Korean patients included in the global PALOMA3 trial provides evidence that combining palbociclib with fulvestrant is an effective strategy to overcome endocrine resistance in women with hormone receptor positive (HR+), HER2 negative (HER2-) advanced breast cancer.

20 Dec 2015

New discovery may soon make prostate cancer cells easier to destroy

A newly discovered connection between two common prostate cancer treatments may soon make prostate cancer cells easier to destroy. Drugs that could capitalize on the discovery are already in the pipeline, and a clinical trial to test whether the finding could improve treatments for prostate cancer patients could be only a few years away.

20 Dec 2015

Chi-Med announces initiation of Phase III sulfatinib registration trial in patients with NETs in China

Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited, its drug R&D subsidiary, has initiated SANET-ep, a Phase III sulfatinib (HMPL-012) registration trial in China in patients with extra-pancreatic neuroendocrine tumors ("NETs"), which are all non-pancreatic NETs, including, for example, NETs originating in the lymph, lung and across the gastrointestinal tract.

18 Dec 2015

Researchers elucidate structure of mTORC1 protein

For a long time it has been known that the protein TOR - Target of Rapamycin - controls cell growth and is involved in the development of diseases such as cancer and diabetes. Researchers at the University of Basel's Biozentrum together with scientists from ETH Zurich have now examined the structure of mammalian TOR complex 1 (mTORC1) in more detail.

18 Dec 2015

UCA researchers identify compounds that favour generation of new neuronal cells

Many neurology pathologies cause irreversible loss of neurons. They are mostly the so-called neurodegenerative diseases although there exist other causes for a focal loss of neurons, as it is the case in strokes or traumatic brain injuries. All these pathologies lack nowadays of an efficient treatment not being possible to regenerate dead neurons. In fact, although the brain has the ability to regenerate as many studies has proved, this regeneration is very low, ranging from 0.2% to a maximum of 10% depending on the type of injury and the damaged area.

17 Dec 2015

Researchers discover novel way to enhance, restore cancer suppressor activity in B-ALL

Researchers at Penn State College of Medicine, working with Chinese and American colleagues, have discovered a novel way to enhance and restore cancer suppressor activity in B-cell acute lymphoblastic leukemia, resulting in better outcomes in a pre-clinical model of the disease. The finding could pave the way for a new class of drugs for this and other forms of leukemia.

15 Dec 2015

$Ibrutinib ‘new standard’ for relapsed, refractory mantle cell lymphoma$

Ibrutinib ‘new standard’ for relapsed, refractory mantle cell lymphoma

Phase III trial findings suggest that patients with relapsed or refractory mantle cell lymphoma derive significantly greater benefits from ibrutinib than from temsirolimus therapy.

14 Dec 2015

Combination treatment provides effective one-two punch against prostate cancer

Results from a long-term clinical trial conducted by cancer researchers at Houston Methodist Hospital show that combining radiation treatment with "suicide gene therapy," a technique in which prostate cancer cells are genetically modified so they signal a patient's immune system to attack them, provides a safe and effective one-two punch against the disease.

12 Dec 2015

Alecensa (alectinib) approved for treatment of people with advanced ALK-positive NSCLC

The U.S. Food and Drug Administration today approved Alecensa (alectinib) to treat people with advanced (metastatic) ALK-positive non-small cell lung cancer (NSCLC) whose disease has worsened after, or who could not tolerate treatment with, another therapy called Xalkori (crizotinib).

11 Dec 2015

Lilly, Merck announce another immuno-oncology collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck's KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types.

10 Dec 2015

NeoGenomics introduces NeoLAB Solid Tumor Monitor, NeoLAB BTK Inhibitor Acquired Resistance test

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today an expansion of its liquid biopsy testing menu to include two new tests, a NeoLAB Solid Tumor Monitor and a NeoLAB BTK Inhibitor Acquired Resistance test.

8 Dec 2015

First targeted treatment to improve survival of high-risk patients with acute myeloid leukemia

Midostaurin added to standard chemotherapy is the first targeted treatment to improve survival of a high-risk, genetically defined subgroup of patients with acute myeloid leukemia (AML), reported Dr. Richard Stone, of Dana-Farber Cancer Institute, on behalf of the Alliance for Clinical Trials in Oncology group, in a plenary session at the 57th American Society of Hematology Annual Meeting and Exposition in Orlando.

8 Dec 2015

Amgen’s Phase 2 data supports safety, efficacy of BLINCYTO in ALL patients with minimal residual disease

Amgen today announced that new data from three Phase 2 trials support the efficacy and safety of BLINCYTO (blinatumomab) in adults with acute lymphoblastic leukemia (ALL).

8 Dec 2015

New approaches to treating leukemia, lymphoma and myeloma

New, highly targeted treatment approaches for leukemia, lymphoma, and myeloma to be presented today at the 57th American Society of Hematology Annual Meeting and Exposition represent a tremendous expansion of oral and intravenous therapy options for patients with blood cancers.

7 Dec 2015

Ibrutinib more effective than traditional chemotherapy in older untreated patients with CLL

A multi-center, international, randomized, Phase III study of older untreated patients with chronic lymphocytic leukemia (CLL) demonstrated that ibrutinib, a kinase inhibitor, is significantly more effective than traditional chemotherapy with chlorambucil.

7 Dec 2015

Potential for chemotherapy-free standard of care in advanced mantle cell lymphoma

The combination of ibrutinib and rituximab shows activity in patients with relapsed or refractory mantle cell lymphoma, suggests research published in The Lancet Oncology.

2 Dec 2015

Discovery may lead to potential new therapeutic approach to eradicate blood cancers

An international team of scientists, headed by researchers at UC San Diego School of Medicine and UC San Diego Moores Cancer Center, report that decreases in a specific group of proteins trigger changes in the cancer microenvironment that accelerate growth and development of therapy-resistant cancer stem cells (CSCs).

1 Dec 2015

Researchers discover drug target and genetic pathway for graft-versus-host disease

A Seattle Children's Research Institute lab has discovered a genetic pathway that can be targeted with existing drugs to prevent graft-versus-host disease (GVHD), a common and deadly complication of bone marrow transplants.

30 Nov 2015

Kinase News and Research

Scientists outline molecular blueprints of tiny cellular 'nanomachine'

TSRI-led study finds potential new therapeutic approach for hard-to-treat breast cancers

Combination therapy can help overcome endocrine resistance in women with advanced breast cancer

New discovery may soon make prostate cancer cells easier to destroy

Chi-Med announces initiation of Phase III sulfatinib registration trial in patients with NETs in China

Researchers elucidate structure of mTORC1 protein

UCA researchers identify compounds that favour generation of new neuronal cells

Researchers discover novel way to enhance, restore cancer suppressor activity in B-ALL

Ibrutinib ‘new standard’ for relapsed, refractory mantle cell lymphoma

Combination treatment provides effective one-two punch against prostate cancer

Alecensa (alectinib) approved for treatment of people with advanced ALK-positive NSCLC

Lilly, Merck announce another immuno-oncology collaboration

NeoGenomics introduces NeoLAB Solid Tumor Monitor, NeoLAB BTK Inhibitor Acquired Resistance test

First targeted treatment to improve survival of high-risk patients with acute myeloid leukemia

Amgen’s Phase 2 data supports safety, efficacy of BLINCYTO in ALL patients with minimal residual disease

New approaches to treating leukemia, lymphoma and myeloma

Ibrutinib more effective than traditional chemotherapy in older untreated patients with CLL

Potential for chemotherapy-free standard of care in advanced mantle cell lymphoma

Discovery may lead to potential new therapeutic approach to eradicate blood cancers

Researchers discover drug target and genetic pathway for graft-versus-host disease

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News